期刊文献+

肝星状细胞条件培养基激活ERK1/2通路诱导肝癌细胞增殖及上皮间质转化 被引量:5

Hepatic stellate cell conditioned medium induces proliferation and epithelial-mesenchymal transition via activating ERK1/2 signaling pathway in hepatoma cells
下载PDF
导出
摘要 目的探讨肝星状细胞(HSC)对肝癌细胞(HCC)恶性生物学行为的影响及其相关机制。方法分别培养SMMC-7721肝癌细胞、Hep G2肝癌细胞和LX-2 HSC,采用LX-2 HSC条件培养基(LX2-CM)、丝裂原激活蛋白激酶(MAPK)特异性抑制剂U0126处理肝癌细胞,TranswellTM小室检测肝癌细胞的侵袭和迁移能力,CCK-8法检测细胞的增殖情况,实时定量PCR和Western blot法分别检测两种肝癌细胞磷酸化的胞外信号调节激酶1/2(p-ERK1/2)、ERK1/2、c-Myc、波形蛋白(vimentin)、上皮钙黏素(E-cadherin)的mRNA和蛋白水平。结果 LX2-CM能促进SMMC-7721细胞和Hep G2细胞的增殖、侵袭和迁移,其作用可被U0126阻断。LX2-CM可以上调p-ERK1/2、c-Myc、vimentin的水平,下调E-cadherin的水平;U0126处理细胞后,p-ERK1/2、c-Myc、vimentin的水平显著降低,E-cadherin水平明显升高。结论 LX2-CM能通过ERK1/2通路激活c-Myc,促进肝癌细胞的增殖、侵袭和迁移,并诱导上皮间质转化。 Objective To investigate the influence of hepatic stellate cells( HSCs) on malignant biological behavior of hepatoma cells and related mechanisms. Methods Human hepatoma cell lines SMMC-7721 and Hep G2,and hepatic stellate cell line LX-2 were cultured separately. HSC conditioned medium( LX2-CM),MAPK specific inhibitor U0126 were used to treat hepatoma cells,separately or together. The invasion and migration abilities of hepatoma cells were detected by TranswellTMassay,and cell proliferation was analyzed by CCK-8 assay. The mRNA and protein expression levels of p-ERK1 /2,ERK1 /2,c-Myc,vimentin and E-cadherin were determined by real-time PCR and Western blot analysis,respectively.Results LX2-CM promoted the proliferation,invasion and migration of SMMC-7721 and Hep G2 cells,and these effects were inhibited by U0126. LX2-CM up-regulated the expression levels of p-ERK1 /2,c-Myc,vimentin and down-regulated the expression level of E-cadherin. Conversely,after U0126 treatment,the expression levels of p-ERK1 /2,c-Myc and vimentin decreased significantly,while E-cadherin expression level increased. Conclusion LX2-CM could activate c-Myc via ERK1 /2signaling pathway in hepatoma cells,and consequently promote cell proliferation,invasion and migration,and also induce epithelial-mesenchymal transition.
作者 谢雨潇 廖锐 潘龙 范凯 彭聪 杜成友 XIE Yuxiao LIAO Rui PAN Long FAN Kai PENG Cong DU Chengyou(Department of Hepatobiliary Surgery, First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China)
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2017年第2期210-214,219,共6页 Chinese Journal of Cellular and Molecular Immunology
基金 国家临床重点专科建设项目([2012]649号) 国家自然科学基金(81301656) 重庆市渝中区科委基础与前沿研究计划项目(20140109)
关键词 肝星状细胞 肝细胞癌 ERK1/2信号通路 增殖 上皮间质转化 hepatic stellate cells(HSCs) hepatocellular carcinoma ERK1 /2 signal pathway proliferation EMT
  • 相关文献

参考文献1

二级参考文献10

  • 1Yabing Mu,Shyam Kumar Gudey,Maréne Landstr?m.Non-Smad signaling pathways[J]. Cell and Tissue Research . 2012 (1)
  • 2Yoko Katsuno,Samy Lamouille,Rik Derynck.TGF-β signaling and epithelial–mesenchymal transition in cancer progression[J]. Current Opinion in Oncology . 2013 (1)
  • 3Ju Dong Yang,Ikuo Nakamura,Lewis R. Roberts.The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets[J]. Seminars in Cancer Biology . 2010 (1)
  • 4Hong-Wu Xin,Chenwi M Ambe,Danielle M Hari,Gordon W Wiegand,Tyler C Miller,Jin-Qiu Chen,Andrew J Anderson,Satyajit Ray,John E Mullinax,Tomotake Koizumi,Russell C Langan,Douglas Burka,Michelle A Herrmann,Paul K Goldsmith,Alexander Stojadinovic,Udo Rudloff,Snorri S Thorgeirsson,Itzhak Avital.Label-retaining liver cancer cells are relatively resistant to sorafenib[J]. Gut . 2013 (12)
  • 5Haraguchi, Naotsugu,Ishii, Hideshi,Mimori, Koshi,Tanaka, Fumiaki,Ohkuma, Masahisa,Kim, Ho Min,Akita, Hirofumi,Takiuchi, Daisuke,Hatano, Hisanori,Nagano, Hiroaki,Barnard, Graham F,Doki, Yuichiro,Mori, Masaki.CD13 is a therapeutic target in human liver cancer stem cells[J]. Journal of Clinical Investigation . 2010 (9)
  • 6Masatoshi Kudo,Kazuho Imanaka,Nobuyuki Chida,Kohei Nakachi,Won-Young Tak,Tadatoshi Takayama,Jung-Hwan Yoon,Takeshi Hori,Hiromitsu Kumada,Norio Hayashi,Shuichi Kaneko,Hirohito Tsubouchi,Dong Jin Suh,Junji Furuse,Takuji Okusaka,Katsuaki Tanaka,Osamu Matsui,Michihiko Wada,Iku Yamaguchi,Toshio Ohya,Gerold Meinhardt,Kiwamu Okita.Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J].European Journal of Cancer.2011(14)
  • 7Kosuke Mima,Hiromitsu Hayashi,Katsunori Imai,Hideyuki Kuroki,Shigeki Nakagawa,Hirohisa Okabe,Akira Chikamoto,Masayuki Watanabe,Toru Beppu,Hideo Baba.High CD44s expression is associated with the EMT expression profile and intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy[J].Journal of Hepato-Biliary-Pancreatic Sciences.2013(4)
  • 8Virginia Hernandez–Gea,Sara Toffanin,Scott L. Friedman,Josep M. Llovet.Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma[J].Gastroenterology.2013(3)
  • 9Hung Huynh,Pierce Kah Hoe Chow,Wai Ming Tai,Su Pin Choo,Alexander Yaw Fui Chung,Hock Soo Ong,Khee Chee Soo,Richard Ong,Ronald Linnartz,Michael Ming Shi.Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma[J].Journal of Hepatology.2011(3)
  • 10Bin-Zhi Qian,Jeffrey W. Pollard.Macrophage Diversity Enhances Tumor Progression and Metastasis[J].Cell.2010(1)

共引文献5

同被引文献20

引证文献5

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部